Pulse Biosciences will present its nPulse Cardiac Catheter and nanosecond pulsed‑field ablation (nsPFA) technology at the Heart Rhythm Society 2026 Annual Meeting in Chicago, Illinois, from April 23‑26. The company will highlight late‑breaking clinical trial updates, including one‑year outcomes from its European feasibility study, in a series of sessions scheduled throughout the conference.
The European feasibility study enrolled 150 patients and reported high procedural success rates: 100% at 6 months and 96% at 12 months, with durable pulmonary vein isolation. These results underscore the potential of nsPFA to deliver precise, nonthermal ablation with improved safety and durability compared to traditional thermal methods.
Pulse’s presentation schedule includes a 11:45‑11:55 a.m. session on Saturday, April 25, featuring Dr. Vivek Reddy’s late‑breaking clinical science talk. Additional sessions include a 1:10‑1:20 p.m. presentation on Friday, April 24, and a 9:40 a.m.‑11:10 a.m. live case summit on Thursday, April 23.
Pulse’s strategic focus on accelerating the nPulse Cardiac Catheter program is reinforced by an analyst event on April 25 in Chicago, where management will discuss the study results and the clinical roadmap. The event is expected to attract electrophysiologists and potential commercial partners, positioning Pulse for future regulatory approvals.
Pulse’s nsPFA technology differentiates itself from thermal ablation by delivering nanosecond pulses that ablate tissue while sparing adjacent structures. The high procedural success and durability observed in the European study suggest that the technology could offer a best‑in‑class solution for atrial fibrillation, potentially accelerating market adoption and strengthening Pulse’s competitive position.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.